These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 17729019)
1. Pharmacotherapy with atomoxetine for US children and adolescents. Bhatara VS; Aparasu RR Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Sankaranarayanan J; Puumala SE; Kratochvil CJ Curr Med Res Opin; 2006 Aug; 22(8):1475-91. PubMed ID: 16870073 [TBL] [Abstract][Full Text] [Related]
3. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder. Van Brunt DL; Johnston JA; Ye W; Pohl GM; Sun PJ; Sterling KL; Davis ME Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017 [TBL] [Abstract][Full Text] [Related]
4. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808 [TBL] [Abstract][Full Text] [Related]
5. Decreased use of clonidine following treatment with atomoxetine in children with ADHD. Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457 [TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824 [TBL] [Abstract][Full Text] [Related]
7. Physician and patient factors associated with the prescribing of medications for sleep difficulties that are associated with high abuse potential or are expensive: an analysis of data from the National Ambulatory Medical Care Survey for 1996-2001. Rasu RS; Shenolikar RA; Nahata MC; Balkrishnan R Clin Ther; 2005 Dec; 27(12):1970-9. PubMed ID: 16507384 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404 [TBL] [Abstract][Full Text] [Related]
9. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
10. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A; Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422 [TBL] [Abstract][Full Text] [Related]
12. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder]. Davids E; Gastpar M Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782 [TBL] [Abstract][Full Text] [Related]
13. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169 [TBL] [Abstract][Full Text] [Related]
14. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Sasané R; Hodgkins P; Meijer W Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165 [TBL] [Abstract][Full Text] [Related]
15. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703 [TBL] [Abstract][Full Text] [Related]
16. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Gibson AP; Bettinger TL; Patel NC; Crismon ML Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655 [TBL] [Abstract][Full Text] [Related]
17. [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample]. Escobar R; Soutullo C; San Sebastián J; Fernández E; Julián I; Lahortiga F Actas Esp Psiquiatr; 2005; 33(1):26-32. PubMed ID: 15704028 [TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR; Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134 [TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Prince JB Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724 [TBL] [Abstract][Full Text] [Related]
20. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Waxmonsky JG Essent Psychopharmacol; 2005; 6(5):262-76. PubMed ID: 16222911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]